Supporting Product Development Through Loans to and Investments in Business Partners
First written in FY2019. 5 of 10 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2025.
The whole theme swung hardest in 2021: 2 of 9 companies on the "Worse" side.
17 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「Listed investments whose number of shares increased during the fiscal year Unlisted shares 1 ¥637 million To strengthen the relationship with the company, the supplier of atrial septal defect closure devices.」
The company made an additional investment of ¥637 million in 1 unlisted company to strengthen its relationship with the supplier of atrial septal defect closure devices. - FY2023AdvancedAnnual report
「Listed investments whose number of shares increased during the fiscal year Unlisted shares 1 ¥220 million To strengthen the cooperative relationship for the development and sale of cell-delivery catheters.」
The company invested ¥220 million in 1 unlisted company to strengthen its cooperation in the development and sale of cell-delivery catheters. - FY2023-Q2AdvancedAnnual report
「Fixed assets increased by ¥1.410 billion from the end of the previous consolidated fiscal year to ¥29.455 billion. This was mainly due to increases of ¥631 million in intangible fixed assets and ¥710 million in long-term loans.」
Long-term loans increased by ¥710 million from the end of the previous consolidated fiscal year, with the increase in investments and loans, including loans to business partners and others, reflected in the company's financial position. - FY2021AchievedAnnual report
「During the fourth-quarter consolidated accounting period, the company executed a waiver of claims and a debt-to-equity swap for the loans and other receivables subject to the allowance for doubtful accounts. As a result, it recorded a ¥2.347 billion loss on waiver of claims, a ¥2.389 billion loss on the debt-to-equity swap, and a ¥1.226 billion provision for an allowance for doubtful accounts on the remaining loans and other receivables.」
Regarding product development support through loans, the company waived claims against the relevant business partner and executed a debt-to-equity swap, recording the related losses and provisions. - FY2021-Q3Decision to waive claims against and execute a DES for a loan recipientAnnual report
「Following consideration of the business relationship and financial condition of the company, we decided to waive the long-term loans and accrued interest owed by the company and execute a debt-to-equity swap. Accordingly, we recorded a ¥3.364 billion provision for an allowance for doubtful accounts in the third-quarter consolidated accounting period.」
Regarding loans to suppliers intended to support product development, the company decided to waive the claims and execute a debt-to-equity swap, and recorded a ¥3.364 billion provision for an allowance for doubtful accounts. - FY2021-Q2Continued recognition of provisions related to loans to EndologixAnnual report
「Including the provision for an allowance for doubtful accounts on loans to the company, the company recorded ¥788 million in expenses outside operating income.」
Regarding loans to business partners intended to secure the product pipeline and for other purposes, recognition of provisions following Endologix's filing for financial restructuring proceedings continued into the second quarter. - FY2021-Q1Recognition of an allowance for doubtful accounts following the borrower's bankruptcy filingAnnual report
「The company recorded ¥625 million in expenses outside operating income, including the provision for an allowance for doubtful accounts on loans to the company.」
Regarding loans to business partners intended to secure the product pipeline and for other purposes, the company recorded ¥625 million in expenses related to the provision for an allowance for doubtful accounts on loans to Endologix following its filing for financial restructuring proceedings. - FY2020-Q3AdvancedAnnual report
「This was mainly due to a ¥929 million increase in construction in progress included in property, plant and equipment, and a ¥614 million increase in investment securities included in Other under investments and other assets.」
Within the investment and lending base, including support for product development by business partners and others, long-term loans increased by ¥454 million from the end of the previous consolidated fiscal year to ¥7.526 billion. - FY2020-Q2AdvancedAnnual report
「This was mainly due to a ¥3.254 billion decrease in cash and deposits, while inventories increased by ¥828 million and short-term loans included in Other increased by ¥749 million. Property, plant and equipment and other fixed assets also increased by ¥1.342 billion from the end of the previous consolidated fiscal year to ¥27.460 billion. This was mainly due to a ¥1.023 billion increase in construction in progress included in property, plant and equipment, and a ¥454 million increase in long-term loans included in investments and other assets.」
Short-term loans increased by ¥749 million and long-term loans by ¥454 million, with the expansion of loans outstanding to business partners and others reflected in the company's financial position. - FY2019First statedAnnual report
「By providing loans and equity investments to these business partners, we seek to strengthen our cooperative relationships and secure the product pipeline by supporting stable product development.」
The company explicitly identified loans and equity investments in highly independent medical device manufacturers and other companies as a means of strengthening cooperative relationships and securing the product pipeline. Long-term loans outstanding at the end of the period amounted to ¥7.052 billion.